Date of Graduation
Bachelor of Science in Biological Engineering
Biological and Agricultural Engineering
Recent studies have shown that human embryonic stem cells possess the ability to differentiate into almost any cell type in the bod and they can self-renew in culture conditions (Baetge, D'Amour et al. 26). As the number of Americans with Type 1 Diabetes continues to increase, innovative methods of treating this chronic illness must be developed in order to improve the quality of life for the affected individuals. Human embryonic stem cells (hESCs) have shown the potential to differentiate successfully into insulin-secreting Î²-cells, and these cultured Î²-cells can be used for cell-treatment therapies to replace the deficient Î²-cells in diabetes patients (Jiang et al. 2007 and Kroon et al. 2008). However promising the capabilities of hESCs seem in treating Type 1 Diabetes, they still contain different genetic information than that of the recipient, therefore the donated Î²-cells risk rejection. To overcome this problem, induced pluripotent stem cells (iPSCs) can be compared to hESCs with respect to their differentiation into Î²-cells since they also can differentiate into almost any cell type (Nishikawa et al. 2008). Induced pluripotent stem cells are derived from reprogramming adult somatic cells back to an embryonic cell-like state, so they would be especially effective in disease treatment since the new Î²-cells produced would contain the patient's own genetic information and therefore the threat of rejection is low.
stem cell research, insulin, diabetes
Rutledge, K. (2011). Enhancing the differentiation efficiency of human embryonic stem cells into insulin-secreting Î²-cells. Biological and Agricultural Engineering Undergraduate Honors Theses Retrieved from https://scholarworks.uark.edu/baeguht/11